Short Interest in Edesa Biotech, Inc. (NASDAQ: EDSA) Declines 21.3%
Edesa Biotech, Inc. (NASDAQ: EDSA) was the target of a significant drop in short interest rates during the month of December. As of December 15, there was short interest totaling 270,100 shares, down 21.3% from the total of 343,100 shares as of November 30. Based on an average daily volume of 322,200 shares, the short-term interest rate is currently 0.8 days. About 3.6% of the company’s shares are sold short.
Separately, HC Wainwright began covering Edesa Biotech in a research report on Monday, December 20. They set a “buy” rating and a target price of $ 16.00 for the stock.
Institutional investors have recently increased or reduced their stakes in the company. UBS Group AG increased its stake in Edesa Biotech shares by 42.1% in the third quarter. UBS Group AG now owns 5,369 shares of the company valued at $ 39,000 after purchasing an additional 1,590 shares during the period. Verition Fund Management LLC acquired a new position in shares of Edesa Biotech in the third quarter valued at approximately $ 100,000. 180 Wealth Advisors LLC acquired a new position in shares of Edesa Biotech in the second quarter valued at approximately $ 70,000. Dimensional Fund Advisors LP acquired a new position in shares of Edesa Biotech in the third quarter valued at approximately $ 115,000. Finally, Virtu Financial LLC increased its stake in Edesa Biotech shares by 17.4% in the second quarter. Virtu Financial LLC now owns 18,938 shares of the company valued at $ 100,000 after purchasing an additional 2,800 shares during the period. Institutional investors own 1.98% of the shares of the company.
EDSA stock opened at $ 5.38 on Friday. Edesa Biotech has a twelve month minimum of $ 4.15 and a twelve month maximum of $ 12.00. The stock has a market cap of $ 72.74 million, a P / E ratio of -4.98 and a beta of 0.56. The company’s 50-day mobile average price is $ 6.32, and its 200-day mobile average price is $ 6.10.
Edesa Biotech (NASDAQ: EDSA) last released its quarterly results on Tuesday, December 28. The company reported ($ 0.27) earnings per share for the quarter, beating Thomson Reuters’ consensus estimate of ($ 0.37) by $ 0.10. As a group, stock analysts predict that Edsa Biotech will post earnings per share of -1.32 for the current year.
Edesa Biotech Company Profile
Edesa Biotech, Inc is a biopharmaceutical company, which focuses on the acquisition, development and commercialization of clinical stage drugs for inflammatory and immune diseases with clearly unmet medical needs. The Company’s product candidate, EB01, is a nonsteroidal anti-inflammatory drug for chronic allergic contact dermatitis (CDA), a common and potentially debilitating condition and occupational disease.
See also: What are the qualifications of a portfolio manager?
This instant news alert was powered by storytelling technology and financial data from MarketBeat to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team before publication. Please send any questions or comments about this story to [email protected]
Should you invest $ 1,000 in Edesa Biotech now?
Before you consider Edesa Biotech, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat identified the five stocks that top analysts quietly whisper to their clients to buy now before the broader market takes hold of… and Edesa Biotech was not on the list.
While Edesa Biotech currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better bets.
See the 5 actions here